HS Rugo

783 citations

49 papers · 561 indexed · h-index 13

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
Cancer Research top 10%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics

Papers in

Oncology 35
- Cancer Treatment and Pharmacology 19
- HER2/EGFR in Cancer Research 10
- PARP inhibition in cancer therapy 4
Cancer Research 16
- Breast Cancer Treatment Studies 12
- Cancer Genomics and Diagnostics 5

Co-authors: CA Linker CA Ries LE Damon Vassiliki Karantza Antoinette R. Tan Hiroji Iwata S-A. Im Sanatan Saraf
Journals: Cancer Research (46 papers)Blood (2 papers)Bone Marrow Transplantation (1 paper)
Partner nations: United States Germany France

In The Last Decade

HS Rugo

49 papers receiving 548 citations

Peers

Countries citing papers authored by HS Rugo

Since Specialization

Citations

This map shows the geographic impact of HS Rugo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by HS Rugo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites HS Rugo more than expected).

Fields of papers citing papers by HS Rugo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by HS Rugo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by HS Rugo. The network helps show where HS Rugo may publish in the future.

Co-authorship network

The 25 scholars most cited alongside HS Rugo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with HS Rugo Line = papers co-authored together HS Rugo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract PD2-12: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers Cancer Research ·HS Rugo, K. Białowicz, 健二河野, Claudine Isaacs, IA Mayer, Vered Stearns, Rita Nanda, Julie R. Nangia, F Kiani Ndeh, 基樹近藤, Bose Kochupurakkal, Antonio C. Wolff, Geoffrey I. Shapiro	2019	1
2	Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial Cancer Research ·Dejan Juric, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, HS Rugo, Hiroji Iwata, Pierfranco Conté, IA Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masanori Takahashi, Zsuzsanna Pápai, JM Jakwong, David Mills, C. Wilke, Dalila Sellami, Fabrice André	2019	45
3	Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation Cancer Research ·Jennifer K. Litton, HS Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung Ho Lee, Louis Fehrenbacher, Rinat Yerushalmi, Sun Li-na, Miguel Martín, Henri Roché, Y-H Im, Guillermo Aureliano, Sudheer Vemuru, S. Z. A. Shah, W. Eiermann, JL Blum	2018	40
4	Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups Cancer Research ·HS Rugo, RS Finn, Véronique Dièras, Johannes Ettl, Oleg Lipatov, Anil A. Joy, Nadia Harbeck, Aurelio Castrellon, Tan Chai Beng, A. Mori, Rose Malchelosse-Fournier, Cen Huang, Х.Н. МАГОМЕДОВА, DJ Slamon	2018	11
5	Abstract P1-07-04: Physical activity, weight and outcomes in patients receiving first-line chemotherapy for metastatic breast cancer: Results from CALGB 40502 (Alliance) Cancer Research ·JA Ligibel, Clouston Hj, HS Rugo, HJ Burstein, D. Toppmeyer, Ilinka Martinović, X. Cynthia, Do-Hoon Kiem, EP Winer, M. Seppänen	2018	1
6	Abstract OT2-07-05: A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC) Cancer Research ·Valérie Agosta-Ives, HS Rugo, Heather Horne, Д. С. Андреев, D M Goldenberg, J. O’Shaughnessy	2018	2
7	Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial Cancer Research ·Virgil Rouquette-Campredon, Nicholas C. Turner, Audrey Mailliez, Johannes Ettl, M Sulpasso, Sun Li-na, Judith Balmañà, SA Hurvitz, Andrew Wardley, PA Fasching, Corneliu Tudor, Linda Nguyen, S. Z. A. Shah, Mark E. Robson, HS Rugo	2018	3
8	Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) Cancer Research ·Sylvia Adams, Sherene Loi, D. Toppmeyer, Bastian Buderer, Michelino De Laurentiis, Rita Nanda, EP Winer, Hirofumi Mukai, Kenji Tamura, Koh Y, MC Liu, Hiroji Iwata, L Ryvo, Pauline Wimberger, HS Rugo, Antoinette R. Tan, Maria Cecilia Sambrano Vieira, Yi Ding, Vassiliki Karantza, Peter Schmid	2018	22
9	Abstract GS3-06: Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC) Cancer Research ·HS Rugo, M. Seppänen, Alvaro Moreno‐Aspitia, Alan P. Lyss, Clouston Hj, K. Białowicz, Lars R. McNaughton, Zamora de Pedro C, LA Carey, Ruwayda Haibe, Deborah Toppmeyer, Mario R. Velasco, Intan Nurmalasari Simaremare, Do-Hoon Kiem, Eric P. Winer	2018	4
10	Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases Cancer Research ·HS Rugo, Małgorzata Palac-Siczek, Mario Campone, Agustí Barnadas, Oana Petrenciuc, Alaa Omar Khazbak, F. Çulha, RE Coleman	2017	1
11	Abstract P5-08-06: Comparison of risk prediction with the 21-gene recurrence score (oncotype DX) and the 70-gene signature (MammaPrint) in patients with estrogen receptor-positive early stage breast cancer Cancer Research ·Hongmei Jiang, Neelima Denduluri, Melanie Majure, Tomiris Kaumenova, HS Rugo	2016	1
12	Abstract P4-11-08: Impact of treatment on quality of life (QOL) in the BEACON study, a randomized phase III trial of etirinotecan pegol (EP) versus treatment of physician's choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C) Cancer Research ·Javier Cortés, Ahmad Awada, Nilsa Alejandra Chacua-Acosta, HS Rugo, Chris Twelves, S-A Im, Cong Zhao, Ute Hoch, 真平江口, S. Z. A. Shah, Joyce O’Shaughnessy	2016	1
13	Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL Cancer Research ·HS Rugo, O. Olopade, Angela DeMichele, Laura van ‘t Veer, Meredith Buxton, Nola Hylton, Douglas Yee, David Kuptana, Anne M. Wallace, (unknown), Julia Lyandres, 王玫林, Ashish Sanil, Donald A. Berry, Laura J. Esserman	2013	48
14	Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer Cancer Research ·José Baselga, Serafín Morales, Ahmad Awada, JL Blum, Rincón-Hernández LE, Marianne Ewertz, Javier Cortés, Beverly Moy, Abdullah Mahmoud Riyahi, Tufia C. Haddad, Eva Ciruelos, Peter Vuylsteke, Scot Ebbinghaus, E. Im, Lamar Eaton, Jurabek Choriyorov, Christine K. Gause, David Mauro, HS Rugo	2013	3
15	Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) Cancer Research ·SM Tolaney, M. Seppänen, M I Martínez Torre, DA Yardley, Beverly Moy, P. Kelly Marcom, KS Albain, HS Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, LA Carey, Lenn Millbower, AH Partridge, Hao Guo, Do-Hoon Kiem, IE Krop, HJ Burstein, EP Winer	2013	22
16	Abstract S3-5: Myelodysplatic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience. Cancer Research ·JE Karp, Amanda L. Blackford, Kumar Visvanathan, HS Rugo, Beverly Moy, LJ Goldstein, Keith Stockerl‐Goldstein, Leigh Neumayer, TS Langbaum, D Balouchi, Оксана Вікторівна Орєхова, Antonio C. Wolff	2012	6
17	OT3-01-16: A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab (DALO) in Estrogen Receptor Positive (ER+) Breast Cancer. Cancer Research ·Motoki Matsubara Motoki Matsubara, JL Blum, Javier Cortés, HS Rugo, Charles Swanton, Lamar Eaton, Yanlong Song, Claudio Cerón, 英樹有本, José Baselga	2011	1
18	Phase I study of sunitinib in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer. Cancer Research ·Julia Lyandres, Michelle Melisko, Mark M. Moasser, Andrei Goga, Jung‐Won Park, HS Rugo	2009	5
19	Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC). Cancer Research ·Maura N. Dickler, Simone Di Franco, Alison Stopeck, Weining Ma, Nam-Hoon Kim, Julia Lyandres, G. V. Williams, Soumi Lahiri, Michael Arbushites, María Koehler, HS Rugo	2009	12
20	High-dose chemotherapy (CTM) for breast cancer Bone Marrow Transplantation ·LE Damon, K. A. Gridnev, HS Rugo, M Negishi, AR Zander, Michael R. Cassidy, G Cecchi, 因心, David Irwin, Michaël Tracy, CA Ries, CA Linker	2000	12

About HS Rugo

HS Rugo is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Urology and Genetics, having authored 49 papers that have together received 561 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (30 papers), Cancer Treatment and Pharmacology (19 papers), Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (10 papers), Cancer Genomics and Diagnostics (5 papers), PARP inhibition in cancer therapy (4 papers), Acute Myeloid Leukemia Research (3 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). The work is most often cited by research in Oncology (459 citations), Cancer Research (189 citations), Pulmonary and Respiratory Medicine (199 citations), Hematology (59 citations) and Genetics (50 citations). HS Rugo has collaborated with scholars based in United States, Germany and France. Frequent co-authors include CA Linker, CA Ries, LE Damon, Vassiliki Karantza, Antoinette R. Tan, Hiroji Iwata, S-A. Im, Sanatan Saraf, Dina Pietrangelo and Véronique Dièras. Their work appears in journals such as Cancer Research, Blood and Bone Marrow Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact